Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors
Tarfah Al-Warhi, Ahmed A Al-Karmalawy, Ayman Abo Elmaaty, Maha A Alshubramy, Marwa Abdel-Motaal, Taghreed A Majrashi, Medhat Asem, Ahmed Nabil, Wagdy M Eldehna, Marwa Sharaky · 2022
Read Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFRWT and EGFRT790M inhibitors by Tarfah Al-Warhi, Ahmed A Al-Karmalawy, Ayman Abo Elmaaty, Maha A Alshubramy, Marwa Abdel-Motaal, Taghreed A Majrashi, Medhat Asem, Ahmed Nabil, Wagdy M Eldehna, Marwa Sharaky (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-9635468.txt.
Description
Tarfah Al-Warhi and co-authors test two new compounds against cancer cells and a growth receptor that tumors lean on, in work the text dates to 2023. The catalog lists 2022. From a family of pyridine and pyrimidine candidates, compounds 8 and 14 stood out across seven cancer lines. The pair were checked for antioxidant effects, cell death patterns, and cell cycle disruption in a liver cancer line.
Both compounds blocked the receptor's normal form and the drug-resistant mutant form credibly. Computer docking showed how they sit in the target, and absorption modeling rated their drug-like prospects. The authors present the pair as leads worth developing against resistant disease.
Catalog record
| CREATOR | Tarfah Al-Warhi, Ahmed A Al-Karmalawy, Ayman Abo Elmaaty, Maha A Alshubramy, Marwa Abdel-Motaal, Taghreed A Majrashi, Medhat Asem, Ahmed Nabil, Wagdy M Eldehna, Marwa Sharaky |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |